SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Chern J)
 

Sökning: WFRF:(Chern J) > (2020) > Effect of Dapaglifl...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006168naa a2200733 4500
001oai:gup.ub.gu.se/291667
003SwePub
008240528s2020 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/2916672 URI
0247 a https://doi.org/10.1001/jama.2020.19062 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Petrie, Mark C4 aut
2451 0a Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
264 1b American Medical Association (AMA),c 2020
520 a Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.Exploratory analysis of a phase 3 randomized trial conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019.Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy.The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death. This outcome was analyzed by baseline diabetes status and, in patients without diabetes, by glycated hemoglobin level less than 5.7% vs greater than or equal to 5.7%.Among 4744 patients randomized (mean age, 66 years; 1109 [23%] women; 2605 [55%] without diabetes), 4742 completed the trial. Among participants without diabetes, the primary outcome occurred in 171 of 1298 (13.2%) in the dapagliflozin group and 231 of 1307 (17.7%) in the placebo group (hazard ratio, 0.73 [95% CI, 0.60-0.88]). In patients with diabetes, the primary outcome occurred in 215 of 1075 (20.0%) in the dapagliflozin group and 271 of 1064 (25.5%) in the placebo group (hazard ratio, 0.75 [95% CI, 0.63-0.90]) (P value for interaction=.80). Among patients without diabetes and a glycated hemoglobin level less than 5.7%, the primary outcome occurred in 53 of 438 patients (12.1%) in the dapagliflozin group and 71 of 419 (16.9%) in the placebo group (hazard ratio, 0.67 [95% CI, 0.47-0.96]). In patients with a glycated hemoglobin of at least 5.7%, the primary outcome occurred in 118 of 860 patients (13.7%) in the dapagliflozin group and 160 of 888 (18.0%) in the placebo group (hazard ratio, 0.74 [95% CI, 0.59-0.94]) (P value for interaction=.72). Volume depletion was reported as an adverse event in 7.3% of patients in the dapagliflozin group and 6.1% in the placebo group among patients without diabetes and in 7.8% of patients in the dapagliflozin group and 7.8% in the placebo group among patients with diabetes. A kidney adverse event was reported in 4.8% of patients in the dapagliflozin group and 6.0% in the placebo group among patients without diabetes and in 8.5% of patients in the dapagliflozin group and 8.7% in the placebo group among patients with diabetes.In this exploratory analysis of a randomized trial of patients with HFrEF, dapagliflozin compared with placebo, when added to recommended therapy, significantly reduced the risk of worsening heart failure or cardiovascular death independently of diabetes status.ClinicalTrials.gov Identifier: NCT03036124.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
7001 a Verma, Sudodh4 aut
7001 a Docherty, Kieran F4 aut
7001 a Inzucchi, Solvio E4 aut
7001 a Anand, Inder4 aut
7001 a Belohlávek, Jan4 aut
7001 a Böhm, Michael4 aut
7001 a Chiang, Chern-En4 aut
7001 a Chopra, Vijay K4 aut
7001 a de Boer, Rudolf A4 aut
7001 a Desai, Akshay S4 aut
7001 a Diez, Mirta4 aut
7001 a Drozdz, Jaroslaw4 aut
7001 a Dukát, Andre4 aut
7001 a Ge, Junbo4 aut
7001 a Howlett, Johathan4 aut
7001 a Katova, Tzvetana4 aut
7001 a Kitakaze, Masafumi4 aut
7001 a Ljungman, Charlotta,d 1977u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xljcha
7001 a Merkely, Béla4 aut
7001 a Nicolau, Jose C4 aut
7001 a O´Meara, Eileen4 aut
7001 a Vinh, Pham Nguyen4 aut
7001 a Schou, Morten4 aut
7001 a Tereshechenko, SErgey4 aut
7001 a Köber, Lars4 aut
7001 a Kosiborod, Mikhail N4 aut
7001 a Langkilde, Anna Maria,d 19554 aut
7001 a Martinez, Felipe A4 aut
7001 a Ponikowski, Piotr4 aut
7001 a Sabatine, Marc S4 aut
7001 a Sjöstrand, Mikaela,d 1964u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xsjomi
7001 a Solomon, Scott D4 aut
7001 a Johanson, Per4 aut
7001 a Greasley, Peter4 aut
7001 a Boulton, David4 aut
7001 a Bengtsson, Olof4 aut
7001 a Jhund, Pardeep S4 aut
7001 a McMurray, John J V4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org
7730 t JAMAd : American Medical Association (AMA)g 323:14, s. 1353-1368q 323:14<1353-1368x 1538-3598x 0098-7484
8564 u https://jamanetwork.com/journals/jama/articlepdf/2763950/jama_petrie_2020_oi_200021_1617397932.1056.pdf
8564 8u https://gup.ub.gu.se/publication/291667
8564 8u https://doi.org/10.1001/jama.2020.1906

Hitta via bibliotek

  • JAMA (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy